News Related to End Stage Kidney Disease

Blood Pressure Drug Class Linked to Worse Kidney Outcomes in Diabetic Patients, Studies Show

Jun 05, 2026

New research presented at the ERA Congress found DCCB blood pressure medications were associated with a 33% increased risk of major adverse kidney events in Type 2 diabetes patients also receiving RAS and SGLT2 inhibitors. A separate study revealed that diabetic nephropathy patients exhibit the most severe biochemical disturbances, including markedly elevated glycemic indices and significantly impaired renal function compared to other groups.

Eli Lilly Acquires Rights to CSL's IL-6 Inhibitor in $100M Deal

Mar 26, 2026

Eli Lilly has acquired rights to CSL's IL-6 inhibitor clazakizumab in a $100 million deal, expanding its cardiometabolic pipeline. The monoclonal antibody targets chronic inflammation, particularly in cardiovascular conditions. This move follows Lilly's successful obesity and diabetes drugs that drove $65.1 billion in 2025 revenue.

SGLT2 Inhibitors, GLP-1 RAs Show Cardiorenal and Hepatic Benefits in Type 2 Diabetes

Mar 03, 2026

New studies show SGLT2 inhibitors and GLP-1 receptor agonists reduce risks of kidney failure, cardiovascular events, and liver complications in patients with type 2 diabetes, with particularly strong benefits in those with cirrhosis.

Eli Lilly Licenses Clazakizumab from CSL in $100 Million Deal

Feb 18, 2026

CSL Limited has licensed global development and commercialization rights for clazakizumab to Eli Lilly outside of ESKD-related cardiovascular risk. CSL receives $100 million upfront and retains rights to the ESKD indication.